**7. Conclusions**

This work presented a general scenario of the classification, risk factors, genetic alterations, diagnosis, and treatment of NSCLC. We highlighted the anticancer potential of four selected flavonoids against NSCLC: luteolin, naringenin, kaempferol, and baicalein. We documented their sources, derivatives, biosynthesis, pharmacokinetics, and their capacity to inhibit NSCLC-promoting processes. We compiled recent evidence about their ability to interfere with major signaling pathways, transcription factors, membrane-cytoskeleton proteins, and intrinsic apoptotic pathways on NSCLC cell lines.

We also addressed the possibility of using them with current chemotherapy medications or as radiosensitizers and radioprotectors. Finally, we mentioned differences in their structure-activity relationships and summarized their effect on fundamental cellular processes, such as cell proliferation, death, metabolism, migration, and fate. Even though this review presented luteolin, naringenin, kaempferol, and baicalein as prospective drug candidates for NSCLC treatment, further studies are required to assess the efficacy safety and improve their bioavailability.
